REG - GenIP PLC Tekcapital plc - Contract Win

TekcapitalAnnouncement

10/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ0211Ma&default-theme=true

RNS Number : 0211M  GenIP PLC  10 June 2025

 

 

10 June 2025

 

GenIP Plc

("GenIP" or the "Company")

 

Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence
(GenAI) services to help research organisations and corporations commercialise
their innovations, is pleased to announce its expansion into the Republic of
Chile through an engagement for 30 analytical assessment orders from a leading
research institution.

 

This order increases the total value of Invention Evaluator orders received by
GenIP since its IPO in October 2024 to over $850,000 1 .

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"I am delighted to announce another new international contract with a leading
research university, marking GenIP's first entry into the Chilean market. The
institution has purchased 30 Invention Evaluator assessments, to support
technology commercialisation decisions across its research portfolio. This
milestone strengthens GenIP's growing footprint in Latin America and
underscores global demand for its GenAI-enabled services.

 

"GenIP's global expansion is underpinned by a healthy balance sheet that
allows the Company to capitalise on opportunities as they arise. As outlined
in our audited results, the reported Operating Loss of $888,545 included
$358,924 of share-based payments relating to the IPO that are not expected to
recur. Customers typically pay in advance for Invention Evaluator report
orders, providing the Company with operating cash flow and future revenue
visibility, with revenue recognised upon completion and delivery of the report
to the client. These factors help maintain the Company's strong financial
position."

 

 

 

For further information regarding GenIP, please visit https://genip.ai/, or
contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 Novum Securities Limited (Broker)                                         Tel: +44 (0)20 7399 9425

 Jon Belliss                                                               JBelliss@novumsecurities.com

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to
help companies, research institutions and venture funds assess and
commercialise new discoveries. GenIP combines expert human technical review
with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1.   Invention Evaluator: Provides bespoke research reports that assess the
market potential of new technological innovations and discoveries using
AI-driven proprietary software; and

 

2.   Vortechs: which is an executive recruitment platform that through
advanced machine learning algorithms and natural language processing
technologies assists in matching technology organisations with experienced
executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help
organisations to evaluate and commercialise their technological innovations.

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To
achieve this, the Company has established three strategic pillars:

 

●     Organically grow Invention Evaluator and Vortechs' revenue through
institutional and corporate connections as well as increase client pipeline
through marketing, advertising and social media spend.

●     Expand the Generative AI service offerings within Invention
Evaluator and Vortechs' to reach new customers and improve margins.

●     Bolt-on acquisitions of additional Generative AI services that are
helpful to our clients and have demonstrated initial market traction.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

 1  Orders are treated as pre-payments with revenue recognised upon report
production by GenIP and delivery to the client. Typically, pre-payments are
utilised approximately 50% within the first 12 months and the balance over the
following 12-18 months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKRRRVRUNRAR